Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group).

摘要: Abstract In a prospective pilot trial of antithrombotic therapy in the acute coronary syndromes (ATACS) resting and unstable angina pectoris or non-Q-wave myocardial infarction, 3 different regimens prevention recurrent ischemic events were compared for efficacy. Ninety-three patients randomized to receive aspirin (325 mg/day), full-dose heparin followed by warfarin, combination (80 mg/day) plus then warfarin. Trial was added standardized antianginal medication continued months until an end point reached. Analysis, intention-to-treat, 3-month points, revealed following: ischemia occurred 7 (22%) after aspirin, 6 (25%) 16 (43%) combined with warfarin; revascularization 12 (38%) (50%) 22 (60%) infarction 1 patient (3%) n (13%) no deaths but (4%) died warfarin alone; major bleeding (9%) 2 (8%) Recurrent at ± days randomization. those who had angioplasty bypass surgery, performed 4 days. During therapy, died, Q-wave bleed. Most complications consisted blood transfusions during immediately surgery. Only 25% enrolled discharged on because withdrawals. Thus, irrespective regimen used, even aggressive substantial fraction have are referred revascularization. Antithrombotic coupled early intervention recurring ischemia, associated low rate death within first months.